# Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain

> **NCT02101554** · PHASE4 · TERMINATED · sponsor: **Pfizer** · enrollment: 19 (actual)

## Conditions studied

- Moderate-severe Pain

## Interventions

- **DRUG:** Ages 7-11
- **DRUG:** ages 12-17

## Key facts

- **NCT ID:** NCT02101554
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-24
- **Primary completion:** 2019-06-26
- **Final completion:** 2019-06-26
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Pfizer released from post-marketing commitment and study terminated because too few patients in the age group; not because of efficacy or safety issues.
- **Last updated:** 2020-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101554, "Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02101554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*